Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Monte Rosa Therapeutics Inc
(NQ:
GLUE
)
5.390
+0.090 (+1.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
380,858
Open
5.250
Bid (Size)
5.320 (4)
Ask (Size)
5.500 (2)
Prev. Close
5.300
Today's Range
5.182 - 5.450
52wk Range
2.440 - 8.840
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
August 19, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
-5.60%
-5.60%
1 Month
-7.39%
-7.39%
3 Month
+38.56%
+38.56%
6 Month
-22.22%
-22.22%
1 Year
+20.58%
+20.58%
More News
Read More
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics: Q4 Earnings Insights
March 14, 2024
Via
Benzinga
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
July 08, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
June 27, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
June 14, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Leadership Team Promotions
May 30, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
May 21, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 16, 2024
Via
Benzinga
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
May 16, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
May 15, 2024
Via
Benzinga
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 15, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
May 02, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 26, 2024
Via
Benzinga
GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023
March 14, 2024
Via
InvestorPlace
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 14, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
March 11, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst
February 15, 2024
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
January 31, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.